Navigation Links
Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine

SAN FRANCISCO, April 11, 2007 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that a seasonal influenza vaccine formulated with the company's Vaxfectin(TM) adjuvant generated up to 60-fold higher antibody responses than an unformulated vaccine at the same dose in a recently completed study in mice. Formulation of sanofi pasteur's Fluzone(R) commercial vaccine with Vaxfectin(TM) also allowed a nearly 10-fold reduction in vaccine dose while generating equivalent or better antibody responses compared with unformulated vaccine, even at the lowest doses tested. Alain P. Rolland, Pharm.D., Ph.D., the company's Senior Vice President of Product Development, presented the data at the Drug Delivery 2007 meeting (San Francisco, April 9 - 11).

Vical is developing its own Vaxfectin(TM)-formulated DNA vaccine designed to protect against emerging strains of influenza virus that have the potential to cause a pandemic. In previously reported studies conducted at St. Jude Children's Research Hospital, Vical's lead Vaxfectin(TM)-formulated, DNA vaccine candidate provided 100% protection in mice and ferrets against lethal challenges with a highly pathogenic strain of H5N1 influenza virus. Initial human testing of Vical's influenza DNA vaccine is expected to begin in the second half of 2007.

Vical tested the Vaxfectin(TM) adjuvant with Fluzone(R) seasonal influenza vaccine to evaluate its potential to ease the anticipated shortage of stockpiled pandemic influenza vaccine and the limited global vaccine manufacturing capacity. In separate studies conducted by others, stockpiled sanofi pasteur H5N1 pandemic influenza vaccine with no adjuvant achieved target levels of antibodies in less than half the subjects after two 90 mcg doses -- a total of six times the normal 15 mcg dose of each strain that provides 75% to 90% protection against seasonal influenza.

The new Fluzone(R) study data confirm and expan
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
2. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
3. New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
4. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
5. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
6. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
7. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
8. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
9. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
10. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
11. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:5/24/2013)... , May 24, 2013  BD (Becton, Dickinson and ... technology company, announced today that it will present at the ... Thursday, May 30, 2013, at 10:40 a.m. (ET). ... from the BD corporate website at www.bd.com/investors and ... About BD BD is a ...
(Date:5/24/2013)... China Biologic Products, Inc. (Nasdaq: CBPO, "China Biologic" or ... in China , today announced that ... issued by Shanghai RAAS Blood Products Co., Ltd. ("Shanghai ... that on May 21, 2013, Ms. Siu ... shareholders of the Company, and her spouse, Mr. Tung ...
(Date:5/24/2013)... England and BOSTON , May 24, ... discovery and development company, is pleased to announce that it has ... to augment the Company,s business development capabilities in Japan ... more than 15 years of experience in business development, licensing and ... Sciences, Inc., Roche Pharma ( Japan ), Nippon Roche ...
Breaking Medicine Technology:China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2
... Scientist to Present Results at 2007 American ... 09, 2007 /PRNewswire-FirstCall/ -- Cleveland,BioLabs, Inc. , ... of,Protectan CBLB502's efficacy as a mitigator of ... damage in non-human primates. The,Company's Chief Scientific ...
... Pa.--(BUSINESS WIRE)--Apr 9, 2007 -,GlaxoSmithKline (LSE and ... from Study 767905/014 and,provided an update on ... 014, a Phase 3, double blind, placebo-controlled ... long-term safety and,tolerability of alvimopan 0.5 mg ...
Cached Medicine Technology:Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival,Benefits as Mitigator Against Radiation-Induced Damage in Study 2Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival,Benefits as Mitigator Against Radiation-Induced Damage in Study 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 2GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 4GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 5GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 6GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 7
(Date:5/25/2013)... It's not astonishing that holidays are amongst ... are endless, from family, friends and co-workers. Between the ... more than their parents can afford, parties to arrange, ... graduations, birthdays, anniversaries and it seems like an eternal ... become tired and income can’t catch up to the ...
(Date:5/25/2013)... May 25, 2013 Communities of Distinction ... It is the fifth largest media market in the United ... number one visitor destination in Texas and a major convention ... the American West as it is home to many major ... enjoy from sports to the arts. Residents and locals will ...
(Date:5/25/2013)... -- Animals make great companions for senior citizens, but elderly ... are far more likely to crash than those who never ... study included 2,000 licensed drivers aged 70 and older. The ... they drove with their pet in the car. Among ... was twice as high as among those who never drove ...
(Date:5/25/2013)... St Louis, MO (PRWEB) May 25, 2013 ... goal for the Diet Doc team of weight management professionals. ... weight fast and effectively, Diet Doc’s hCG diets ... uncontrollable factors like abuse during childhood like bullying, more control ... not directly capable of dealing with the underlying factors of ...
(Date:5/25/2013)... May 25, 2013 The latest ... from irritable bowel syndrome (IBS) to bloating, constipation, ... the most long-lasting, embarrassing, frustrating and difficult health ... for digestive health have provided a cure ... many factors contributing to digestive health issues, a ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Debuts Their Brand New Beauty Kits 2Health News:Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas 2Health News:Seniors More Likely to Crash When Driving With Pet: Study 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 3Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2
... initiation of lifesaving antiretroviral therapies should be the standard of ... limited medical and financial resources, according to a study led ... Tutu HIV Centre, University of Cape Town, South Africa. ... Internal Medicine that starting antiretroviral therapy (ART) when the ...
... , LOS ANGELES, July 20 Dr. Chugay, a leading ... patch procedure to aid patients with goals of rapid weight loss. , ... over thir ty years of experience and has personally performed ... surgery expert on The Tonight Show , Entertainment Weekly , CNN ...
... , FLEMINGTON, N.J., July 20 A new national ... (82%) do not believe that drugs containing acetaminophen should be pulled ... (Logo: http://www.newscom.com/cgi-bin/prnh/20071204/NYTU133LOGO ) , , ... during July 17-19, to obtain physicians, perceptions of a CNN news ...
... , , NEW YORK, ... controversial and thought provoking topics today, MTV,s "16 & Pregnant" season ... (2.1 million) on Thursday, July 16, ranking as the number one ... their favorite series with the "16 & Pregnant: Life After Labor" ...
... working on H1N1 swine flu vaccine, which should be ready ... U.S. Food and Drug Administration has approved the vaccine to ... , The agency noted that this vaccine will not protect ... pandemic proportions around the world and is expected to return ...
... , GREENFIELD, Wis., July 20 ... nutritional service and meal-planning program for cancer patients. The web-based ... . Founded by cancer survivors, the program is based ... It is available to cancer patients and health care systems ...
Cached Medicine News:Health News:Earlier HIV antiviral treatment can be cost effective in areas of limited resources 2Health News:Dr. Chugay (drchugay.com) - Revolutionary Weight Loss Surgery 2Health News:Docs Say No to Pulling Drugs Containing Acetaminophen off the Market 2Health News:Docs Say No to Pulling Drugs Containing Acetaminophen off the Market 3Health News:MTV's Season Finale of '16 & Pregnant' Hit Series Highs Among Both P12-34 (1.9) and Total Viewers (2.1 Million) Thursday, Ranking as the Number One Primetime Cable Program 2Health News:MTV's Season Finale of '16 & Pregnant' Hit Series Highs Among Both P12-34 (1.9) and Total Viewers (2.1 Million) Thursday, Ranking as the Number One Primetime Cable Program 3Health News:MTV's Season Finale of '16 & Pregnant' Hit Series Highs Among Both P12-34 (1.9) and Total Viewers (2.1 Million) Thursday, Ranking as the Number One Primetime Cable Program 4Health News:MTV's Season Finale of '16 & Pregnant' Hit Series Highs Among Both P12-34 (1.9) and Total Viewers (2.1 Million) Thursday, Ranking as the Number One Primetime Cable Program 5Health News:FDA Approves Seasonal Flu Vaccine for 2009-2010 2Health News:FDA Approves Seasonal Flu Vaccine for 2009-2010 3Health News:Cancer Survivors Launch New Company, TherapEase Cuisine 2
Anterior chamber protein cell meter. Laser flare meter and cell-counting functions are included in this cell meter, with dramatically enhanced measurement of cell volume....
... new SureSigns VS1 is an ... monitor that provides reliable, accurate, ... VS1 is designed to make ... like large, bright, color-coded LED ...
... High-performance monitoring at the patients side and ... monitors provide essential measurements in a compact ... needs of post-operative care, lower acuity environments, ... strong heritage in patient monitoring, the IntelliVue ...
... Built on Philips strong heritage in ... configuration; an extensive clinical measurements menu; built-in ... EASI* derived 12-lead ECG, and arrhythmia analysis; ... is easy to use and operates on ...
Medicine Products: